Overview

A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme

Status:
Completed

Trial end date:
2006-03-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to determine the efficacy of gefitinib (IressaTM) in combination with radiotherapy on patients with glioblastoma multiforme.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Gefitinib